Introduction
============

Amyloid-*β* (A*β*) peptides form cortical plaques, a major feature of Alzheimer\'s disease (AD) neuropathology.[@b1] Approximately 30--50% of brains from the individuals with latent or prodromal AD over age 60 harbor A*β*-pathology in a similar pattern to that seen in AD.[@b1] In the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) study 46% of patients with early mild cognitive impairment (MCI) were A*β*-positive, suggesting that these subjects had prodromal AD, while 54% did not have significant brain A*β* accumulation. These findings, together with many other reports[@b2],[@b3] indicate that clinical assessment alone has limited utility to detect early AD pathology in many individuals. Whether these individuals will later develop cognitive decline and dementia due to AD remains unknown; however, evidence of brain A*β* accumulation increases the risk for progression from clinical dementia rating (CDR) 0 to CDR 0.5 status by fivefold, and conversion from MCI to AD by threefold.[@b4] Therefore, earlier, more accurate, biomarker-based detection of AD-related A*β* pathology is crucial and could potentially offer a greater opportunity for initiation of disease-modifying therapies prior to the advanced stages of AD.

Brain A*β* deposition can be detected by molecular imaging techniques such as positron emission tomography (PET) using an A*β*-specific radioligand, or through measurement of cerebrospinal fluid (CSF) A*β*~1-42~ concentration. Both of these measures show high correlations with postmortem measures of fibrillar A*β*.[@b5]--[@b7] Lumbar puncture, required for CSF sample collection, carries a 4% risk of a clinically significant adverse event (e.g., post-lumbar puncture headache, moderate atypical headache, moderate low back pain, vasovagal episode)[@b8] and is, therefore, unattractive as a population screening tool, particularly in early-stage individuals. Neuroimaging has the advantage of being less invasive and PET tracers have been changing the field by enabling in vivo A*β* plaque detection. However, PET is relatively expensive with limited availability and contributes to the patient\'s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer.[@b9]

There is an emerging literature investigating A*β*-related brain changes using structural MRI (magnetic resonance imaging) describing an association between A*β* burden (e.g., low CSF A*β*~1-42~ or high A*β*-PET binding) and atrophy, especially of the parietal and posterior cingulate regions, extending into the precuneus and medial temporal regions including hippocampus, amygdala, and entorhinal cortex.[@b10]--[@b16] Although not as substantial as the structural studies, arterial spin labeling (ASL) MRI studies also show A*β*-related cerebral blood flow (CBF) changes including reduced CBF in the cingulate, supramarginal gyrus, thalamus, and midbrain, as well as increased CBF in the medial and inferior frontal, precuneus, and inferior parietal regions.[@b17]--[@b19] These findings suggest that A*β* accumulation is associated with structural and CBF changes, both of which can be detected with MRI.

The primary goal of this study was to develop a method to predict which subjects with early MCI have A*β* deposition, by using MRI-detected changes of brain structure and CBF. The study cohort consisted of 67 individuals with early MCI between the ages of 60 and 85 years and 33 A*β*-negative cognitively normal (CN) elderly individuals, to model the normal confounding effects of age, gender, and education, all recruited by ADNI. Global A*β* burden, determined by A*β* PET using ^18^F-AV45 radioligand (florbetapir), served as outcome variable in primary hypotheses testing. The predictors included high-dimensional measures of anatomical shape variations from structural MRI and regional CBF from ASL-MRI, as well as demographics and Apolipoprotein E (ApoE) genotype. Our central hypothesis was that even the earliest A*β*-related structural and CBF changes could be detected in vivo using clinically viable metrics to construct a robust mathematical A*β* prediction model. This will help to develop clinically viable early surrogate biomarkers of AD pathology in prodromal individuals. This will have a broad use in early diagnosis, facilitating initiation of prevention strategies in those at risk, and boost the power of anti-A*β* immunotherapy trials by selecting those at greatest risk of AD. As a secondary goal, we assessed the relative importance of imaging modalities in classification of ^18^F-AV45-positive versus ^18^F-AV45-negative early-MCI individuals.

Methods
=======

Participants
------------

Data used in the preparation of this article were obtained from the ADNI database (adni.loni.ucla.edu). The ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies and non-profit organizations, as a \$60 million, 5-year public private partnership. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as to lessen the time and cost of clinical trials.

The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California -- San Francisco. ADNI is the result of efforts of many co investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. To date, these three protocols have recruited over 1500 adults, ages 55--90, to participate in the research, consisting of CN older individuals, people with early or late MCI, and people with early AD. The follow-up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see [www.adni-info.org](http://www.adni-info.org).

Data for this study were limited to baseline scans from ADNI-GO/2 participants in the ASL-MRI substudy as of June 2013. This cohort included 33 CN elderly individuals (CN) and 67 early-MCI subjects, representative of the broader ADNI-GO/2 CN and early-MCI participants (cf Tables S1--S2). Full inclusion and exclusion criteria for ADNI are described at [www.adni-info.org](http://www.adni-info.org). In brief, CN subjects had mini-mental state examination (MMSE) scores between 24 and 30, a CDR of 0, no evidence of depression, and no memory complaints. Individuals with MCI were classified essentially in the manner described by Petersen,[@b20] but were then further divided into an "early" and "late" group based on performance on the Wechsler Memory Scale--Revised Logical Memory II (WMS-LM). The early-MCI group was defined based on scores between the cutoff of CN and that of the late-MCI group.

Baseline MRIs of CN subjects were used to model the normal confounding effects of age, gender, and education on anatomical shape variation and CBF measures. Previous studies reported that the cumulative and regional A*β* burden in CN subjects correlate with regional brain atrophy and CBF changes.[@b17],[@b10],[@b21] Furthermore, CN subjects at genetic risk for AD by virtue of the ApoE ε4-allele demonstrated regional brain atrophy and CBF differences relative to ε4-noncarriers.[@b22],[@b23] Therefore, we included only the ApoE ε4-noncarrier CN subjects who were identified as A*β*-negative using ^18^F-AV45-PET. Furthermore, ApoE ε2-allele carrier CN and early-MCI subjects were excluded due to sample size limitations. Study group demographics are summarized in Table[1](#tbl1){ref-type="table"}.

###### 

Demographic information of subject groups.

                                           Cognitively healthy elderly   Early MCI      *P*-value
  ---------------------------------------- ----------------------------- -------------- -----------
  Number of subjects                       33                            67             --
  Age                                      72.80 ± 6.04                  69.76 ± 6.61   0.025
  Gender (F/M)                             19/14                         22/45          0.040
  Education                                16.70 ± 2.30                  16.57 ± 2.66   0.788
  ApoE ε4 genotype (ε3/ε3, ε3/ε4, ε4/ε4)   33, 0, 0                      41, 23, 3      \<0.0001
  MMSE                                     29.24 ± 1.06                  28.79 ± 1.21   0.061
  CDR-SB                                   0.02 ± 0.09                   1.23 ± 0.81    \<0.0001
  ADAS-Cog                                 6.42 ± 3.56                   7.65 ± 3.35    0.094
  ^18^F-AV45-PET SUVR                      1.00 ± 0.05                   1.16 ± 0.18    \<0.0001
  ^18^F-AV45-positive (%)                  0%                            50%            \<0.0001

^18^F-AV45-PET
--------------

^18^F-AV45-PET scans were acquired 50--70 min after injection of 10 mCi of tracer. Images underwent a rigorous quality control protocol and were processed to produce final images with standard orientation, voxel size, and 8 mm resolution by the ADNI-PET Core.[@b24] Briefly, scans were analyzed in native space using the subjects' structural MRIs acquired close to the time of the ^18^F-AV45-PET scans. Structural MRIs were segmented into cortical regions using FreeSurfer version 4.5.0 (surfer.nmr.mgh.harvard.edu/). These cortical regions of interest (ROIs) were used to extract ^18^F-AV45-PET uptake from gray matter (GM) in lateral and medial frontal, anterior, and posterior cingulate, lateral parietal, and lateral temporal cortex. Values were normalized to florbetapir-PET uptake in the whole cerebellum. The averaged cortical uptake in this composite ROI was used as the index of florbetapir-PET uptake, that is, standard uptake value ratio (SUVR), in each subject. Furthermore, subjects were characterized as ^18^F-AV45-positive or ^18^F-AV45-negative based on a threshold value of 1.11 for the ^18^F-AV45-SUVR.[@b25]

Multimodality MRI acquisition
-----------------------------

Both high-resolution structural MRI and ASL-MRI were acquired at ADNI-GO/2 sites equipped with 3T Siemens MRI scanners. Two structural MRIs were acquired using a 3D magnetization prepared rapid gradient echo (MPRAGE) T1-weighted sequence with the following parameters: TR/TE/TI = 2300/2.98/900 msec, 176 sagittal slices, within plane field-of-view (FOV) = 256 × 240 mm^2^, voxel size = 1.1 × 1.1 × 1.2 mm^3^, flip angle = 9°, bandwidth = 240 Hz/pix. A designated center selected the MPRAGE image with higher quality and corrected for system-specific image artifacts such as geometry distortion, B1 nonuniformity, and intensity inhomogeneities.[@b26] ASL-MRIs were acquired using the Siemens product proximal inversion with control for off-resonance effects sequence, which is a pulsed ASL sequence using the Q2TIPs technique for defining the spin bolus. The acquisition parameters were: TR/TE = 3400/12 msec, TI1/TI2 = 700/1900 msec, FOV = 256 mm, 24 sequential 4-mm thick slices with a 25% gap between the adjacent slices, partial Fourier factor = 6/8, bandwidth = 2368 Hz/pix, and imaging matrix = 64 × 64.

Anatomical shape variations
---------------------------

Skull, scalp, and extracranial tissue were removed from each structural MRI using the automated Brain Surface Extraction software,[@b27] followed by manual refinement if required. To avoid bias toward a particular subject\'s geometry in analysis of anatomical shape variations, we used the data from CNs to create a study-specific unbiased large deformation brain image template (ULD-template) by applying a framework of large deformation diffeomorphic metric mapping (LDDMM) as described in full elsewhere.[@b28] ULD-template generation incorporated an unbiased approach where all brain images were first simultaneously affine transformed to adjust for global variations in brain positioning and scale, and then simultaneously deformed. Structural MRI of each early-MCI subject was first affine aligned and then nonlinearly warped to this ULD-template using the LDDMM framework. The LDDMM was modeled as an evolution in time, with an associated smooth velocity vector field controlling this evolution. A scalar initial momentum map parameterized the entire geodesic with which the optimal trajectory emanated from the ULD-template to reach a subject brain image on a Riemannian manifold of diffeomorphism.[@b28] These momentum maps uniquely encoded the anatomical shape variations of individual brains relative to the ULD-template.

Cerebral blood flow
-------------------

ASL-MRI processing was performed to obtain partial volume-corrected maps of CBF, as previously described.[@b29]--[@b33] Individual ASL-MRI frames were coregistered using rigid body registration to reduce movement artifacts. Geometric distortion correction on ASL-MRI with respect to the affine-aligned T2-weighted MRI was estimated using a variation image-based approach for correction of susceptibility artifacts.[@b34] Motion and distortion corrected images were normalized to the ASL reference scan signal (the first volume of the ASL acquisitions), without background suppression, to account for B1-field variations. The dynamic ASL data were fitted voxel-by-voxel to a dual compartment perfusion model, which takes into account variable transit times, bolus durations, distributed concentrations of capillary water and restricted brain-blood barrier permeability.[@b35] This model yielded a parametric map for CBF. The ASL reference scan signal without background suppression was rigidly coregistered, first to T2-weighted and then to MPRAGE-MRI, to map the parametric CBF measures to the structural-imaging space, where anatomical tissue compartments were defined by an adaptive fuzzy c-means algorithm.[@b36] Variations of CBF due to partially volumed GM voxels were accounted for by voxel-wise analysis of covariance, in which the tissue compartment estimates were entered as regressors. To account for global variations in CBF between and within individuals, CBF maps were intensity normalized by average CBF in the motor cortex, which is spared in AD. The resultant CBF maps were resampled to the ULD-template image space via the corresponding LDDMM vector fields, estimated for the corresponding structural MRI.

Covariates
----------

We used a general linear model based detrending method to control for any normal confounding effects of age, gender, and education, based on ^18^F-AV45-negative and ApoE ε3/ε3 CN subjects. Adjusted imaging measures of anatomical shape variation and CBF were used for further data analyses.

Neuroimaging correlates of A*β* burden
--------------------------------------

MR imaging provides high-throughput data for discovery of surrogate biomarkers for A*β* pathology, but the high-dimensional data based on a relatively small number of participants inherently comes with significant codependencies and contain a large number of association patterns, most of which are erroneous or redundant. Our goal was to identify which of these are significant associations, with high predictive power. Partial least squares (PLS) regression[@b37] has the ability to handle high-dimension, low sample size, multicollinear data, while searching for modes that explain the maximum covariance between the explanatory and response spaces. We used PLS regression with the neuroimaging measures (i.e., anatomical shape variation and CBF) from each and every imaging voxel as predictors to assess the patterns of neuroimaging-A*β* associations. In joint analysis of anatomical shape variation and CBF measures, we first normalized each imaging data to have unit variance and then combined the data to form a product space defined by their convex combination with a relative weighting coefficient of 0 ≤ *λ* ≤ 1, that is, *λ* = 0 for pure CBF correlates of A*β* and *λ* = 1 for pure anatomical shape variation correlates of A*β*. For a given *λ*, the statistical significance of the neuroimaging-A*β* associations inferred by PLS regression was assessed using the projected data and non-parametric permutation testing. Furthermore, a *λ*-dependent neuroimaging-based A*β* score was calculated by projecting each individual\'s neuroimaging data onto the latent variable (LV) inferred by the corresponding PLS regression.

Classification of A*β*+ early-MCI individuals
---------------------------------------------

To create a mathematical function that best combines the neuroimaging-based A*β* score, demographics (i.e., age, gender, and education), and ApoE genotype to give a binary prediction of A*β*+ in early-MCI individuals, we based our classification model to a logistic regression with least absolute shrinkage and selection operator (LASSO). The neuroimaging-based A*β* score, age, gender, education, and ApoE genotype were the independent predictor variables. The dependent outcome variable was the A*β*+/− dichotomization, based on ^18^F-AV45-PET scans and established standardized ^18^F-AV45 uptake threshold.[@b25] For 10-fold cross-validation of the classifier performance, the data were divided into 10 subsets of cases that had similar size and A*β*+/− distributions. Each subset was left out once, while the other nine was applied to construct a neuroimaging-based A*β* score and a classifier subsequently validated for the unseen cases in the left-out subset. Classifier performance assessment was based on classification accuracy (CA), positive predictive value (PPV), and negative predictive value (NPV). Performance of the best performing classifier with nonimaging factors was referenced to test the added value of neuroimaging in classification of A*β*+/A*β*− early MCI. Finally, to assess the relative importance of structural and ASL imaging data, we constructed the neuroimaging-based A*β* score and classifier for various *λ* values in the range (0, 1) with 0.05 increments.

Results
=======

Demographic characteristics
---------------------------

Demographic characteristics of the subjects are summarized in Table[1](#tbl1){ref-type="table"}. On average, early MCIs were significantly younger than CNs (*t* = 2.29, *P* = 0.02), although still in the same age range. Early-MCI group had disproportionately higher male subjects compared with CN group (*χ*^2^ = 4.23, *P* = 0.04). Consistent with the ADNI recruitment criteria and our study design, early-MCI and CN groups differed in the clinical measure of CDR-SB, ^18^F-AV45-SUVR (two-sample *t*-tests; *P* \< 0.0001), ^18^F-AV45-positive/negative ratio, and ApoE ε4-allele frequency (chi-squared contingency table test; *P* \< 0.0001).

Neuroimaging signatures of brain amyloidosis
--------------------------------------------

Figure[1](#fig01){ref-type="fig"}A shows the spatial signature of the LV inferred by PLS regression for *λ* = 1, that is, anatomical shape variation signature of brain A*β*-burden in early MCI. Dark red/blue and white colors indicate greater contribution of the local anatomical shape variations to the LV, therefore to the structural-A*β* association. Increased ^18^F-AV45-SUVR was associated with anatomical shape variations largely in the frontoparietal cortical regions including inferior parietal, precuneus, supramarginal, postcentral, middle frontal, and to a lesser extent in the temporal lobe regions including superior temporal, entorhinal, hippocampus, and subcortical regions including amygdala, nucleus accumbens, and caudate (*r* = 0.93; *P* \< 0.0001).

![Neuroimaging signatures of brain amyloidosis in early MCI.](acn30001-0160-f1){#fig01}

The spatial signature of the LV inferred by PLS regression for *λ* = 0, that is, CBF signature of brain A*β*-burden in early MCI, is shown in Figure[1](#fig01){ref-type="fig"}B. Hypoperfusion regions are colored in shades of blue and hyperperfusion regions are colored in shades of red. Increased ^18^F-AV45-SUVR was associated with hypoperfusion primarily in the medial temporal regions, including hippocampus, entorhinal, parahippocampus, fusiform, temporal pole, amygdala, as well as with hyperperfusion largely localized in the inferior parietal lobule but also including inferior frontal, postcentral, and precuneus regions (*r* = 0.77; *P* \< 0.0001).

A*β*+ predictive power of the neuroimaging-based A*β* scores alone and in combination with other nonimaging variables
---------------------------------------------------------------------------------------------------------------------

Estimated performances of the LASSO penalized logistic regression classifiers with nonimaging variables (i.e., age, gender, years of education, and ApoE-ε4 genotype) alone and jointly with neuroimaging-based A*β* scores are reported in Table[2](#tbl2){ref-type="table"}. All classifiers considered in this study performed significantly better than chance (*P* \< 0.01). ApoE ε4-genotype jointly with demographics data classified ^18^F-AV45-positive early MCIs with a 69% CA, 73% PPV, and 70% NPV. Both pure structural- and pure ASL-MRI-based A*β* scores outperformed the ApoE ε4-genotype (*P* \< 0.01) and reached higher CAs (79% and 75%, respectively), higher PPVs (81% and 76%, respectively), and higher NPVs (80% and 78%, respectively). A multidisciplinary classifier combining demographics, ApoE ε4-genotype, and neuroimaging-based A*β* scores reached 80--83% CA, 82--85% PPV, and 82--83% NPV in identifying ^18^F-AV45-positive early MCIs.

###### 

Estimated performances of the LASSO penalized logistic regression classifiers in predicting ^18^F-AV45-positivity in early MCI.

  Predictors                                                           CA            PPV           NPV
  -------------------------------------------------------------------- ------------- ------------- -------------
  Demographics (age, gender, years of education)                       0.65 ± 0.03   0.67 ± 0.03   0.66 ± 0.04
  Demographics and ApoE ε4 genotype                                    0.69 ± 0.08   0.73 ± 0.09   0.70 ± 0.10
  Demographics and sMRI-based A*β* burden score                        0.79 ± 0.05   0.81 ± 0.06   0.80 ± 0.07
  Demographics and ASL-based A*β* burden score                         0.75 ± 0.11   0.76 ± 0.12   0.78 ± 0.10
  Demographics and ApoE ε4 genotype and sMRI-based A*β* burden score   0.83 ± 0.03   0.85 ± 0.02   0.83 ± 0.04
  Demographics and ApoE ε4 genotype and ASL-based A*β* burden score    0.80 ± 0.06   0.82 ± 0.06   0.82 ± 0.02

Relative importance of imaging modalities in identifying ^18^F-AV45-positive early MCIs
---------------------------------------------------------------------------------------

Performance of the multidisciplinary classifier as a function of *λ*, relative weighting coefficient for structural MRI and ASL-MRI in the construction of the neuroimaging-based A*β* score, is plotted in Figure[2](#fig02){ref-type="fig"}. Maximal CA (≥83%), PPV (≥87%), and NPV (≥84%) were achieved with 0.25 ≤ *λ* \< 0.5. Added value of multimodality-MRI over unimodality MRI was significant (*P* \< 0.01) only in terms of PPV of the final classifier.

![Performance of the multidisciplinary classifier as a function of *λ*, relative weighting coefficient for structural MRI and ASL-MRI in the construction of the neuroimaging-based A*β* score.](acn30001-0160-f2){#fig02}

Discussion
==========

The major findings of this study were (1) ^18^F-AV45-positive early-MCI subjects could be identified with a CA ≥ 83%, PPV ≥ 87%, and NPV ≥ 84% by a multidisciplinary classifier combining demographics data, ApoE ε4-genotype, and multimodality MRI-based A*β* score; (2) this maximal ^18^F-AV45-positivity classifier performance was achieved with a relative weighting coefficient of 0.25 ≤ *λ* \< 0.5 for structural MRI and ASL-MRI, implying the dominance of CBF changes in predicting ^18^F-AV45-positivity in early MCI; and (3) greater cortical ^18^F-AV45-SUVR in early MCI was associated with patterns of anatomical shape variations predominantly in the fronto-parietal regions, patterns of hypoperfusion in medial temporal cortices, and patterns of hyperperfusion localized to inferior parietal lobule. Taken together these results demonstrate that structural MRI and ASL-MRI can be used to predict the A*β* status of individuals with early MCI.

We previously pursued the use of structural MRI in predicting widespread brain A*β* deposition in individuals with MCI.[@b38] Although the overall objective of this study is similar to our previous work, the contribution of this study is twofold: First, the primary goal of this study was to develop a method to predict which subjects with early MCI have brain A*β* deposition, by using MRI-detected changes of brain structure and CBF. Expected smaller effect size estimates for both functional and structural brain changes make it challenging to adequately power to construct a robust mathematical A*β* prediction model for early-MCI. Second, to the best of our knowledge, this is the first neuroimaging study showing the value of structural MRI and ASL-MRI as predictors of the likelihood of significant A*β* accumulation, both independently and jointly. According to our findings, the added value of multimodal MRI is incremental yet significant especially in terms of the PPV of the proposed early-MCI A*β*-positivity predictor. We demonstrated that with multimodality MRI, basic demographics, and ApoE genotype data, we could achieve an 83% CA with an 87% PPV and an 85% NPV in identifying ^18^F-AV45-positive early-MCI. This multimodality/multidisciplinary classification model outperformed other classifiers considered in this study using either nonimaging factors or unimodality neuroimaging data. Such an A*β*-positivity classifier would greatly improve the efficiency of clinical trials targeting the early disease stages by reducing the number of subjects needed to be screened with A*β*-PET scans or lumbar punctures. Specifically, based on the 87% PPV, to enroll 100 ^18^F-AV45-positive early-MCI participants, screening on structural and CBF variations in addition to age, gender, education, and ApoE genotype can reduce the number needed to screen by 47%, resulting in screening of only 15 additional participants than the targeted number. According to our analyses, the added value of multimodality neuroimaging data to age, gender, education, and ApoE genotype information is a 14% increase in the CA, as well as in PPV and NPV of the final A*β*-positivity prediction model. The 14% difference in PPV and NPV metrics translates to a 20% difference in both the number of subjects needed to screen for recruitment and the number of subjects needed to screen with A*β*-PET scans.

There is an emerging literature investigating A*β*-related brain changes using structural MRI describing an association between A*β* burden (e.g., low CSF A*β*~1-42~ or high A*β*-PET binding) and atrophy, especially of the parietal and posterior cingulate regions, extending into the precuneus and medial temporal regions including hippocampus, amygdala, and entorhinal cortex. This parietotemporal dominant pattern of A*β*-atrophy association is even evident at mild stages of cognitive deficits.[@b10]--[@b16],[@b39]--[@b41] A surprising finding of this study showed that in early MCI, A*β*-related anatomical shape variations were widespread, and showed a superior--inferior gradient with anatomical shape variations in the parietal and frontal regions exhibiting greater associations with A*β*-burden than temporal and occipital regions. This early-MCI anatomical shape variation signature of brain A*β* is mainly in agreement with the A*β*-accumulation patterns reported for elderly individuals,[@b2],[@b42] affecting predominantly parietal and frontal brain regions more than temporal and occipital brain regions with a superior--inferior gradient.[@b2],[@b42] This suggests a localized effect of A*β* pathology on brain structure in early-MCI individuals. In contrast to the structural-A*β* association pattern, the early-MCI CBF signature of brain A*β* involved several AD-related neurodegeneration brain regions, in agreement with many previous reports of altered tempero-parietal CBF in AD continuum.[@b30],[@b43]--[@b52] Our finding of spatial pattern CBF-A*β* association being distributed rather than being localized to A*β* accumulation sites suggests a greater involvement of a memory network including hippocampal complex in A*β*-related CBF changes in early MCI. Future studies examining the temporal dynamics of A*β* accumulation, atrophy, and CBF changes could further our understanding of pathophysiological processes in early disease stages.

The strength of this study is the approach we used to predict the likelihood of significant A*β* accumulation in early MCI. We applied a combination of state-of-the-art, yet clinically feasible, 3T neuroimaging techniques for quantification of voxel-based brain anatomical and CBF changes, and modern multivariate statistical analysis methods that allow simultaneous testing of variations across modalities and brain regions to maximally exploit information and to relate these high-dimensional brain alterations to measure of global brain A*β* accumulation. Although neuroimaging research has made major progress in linking A*β* and AD-related neurodegeneration, the majority of these studies have analyzed each neuroimaging modality in isolation, ignoring relationships between the measures that might carry important predictive information for A*β*-positivity. Moreover, aside from a small number of studies,[@b38],[@b40],[@b53] most neuroimaging studies and especially those using structural MRI, evaluate variations in the brain region-by-region, ignoring the network connectivity changes that could reflect the pathological footprint of A*β* accumulation.

A potential limitation of this study is that findings from the ADNI may not precisely generalize to general population. In particular, ADNI population represents a clinical trial population and not an epidemiologically selected real life population. Other study limitations include the inherent limitations of the ASL technique, namely that it has low signal-to-noise ratio, and is susceptible to motion artifacts. Finally, our study does not explain the mechanisms behind the detected A*β*-related structural and CBF variations. Furthermore, the neuroimaging signature of brain amyloidosis estimated by the PLS regression approach represents the parsimonious set of neuroimaging variables (i.e., anatomical shape variation or CBF measures from a subset of brain tissue voxels) that cumulatively explain the variance in A*β* burden maximally. These parsimonious set of neuroimaging voxels identified as good predictors of A*β* burden is expected to be smaller than the set of neuroimaging voxels potentially with significant A*β*-association based on conventional voxel-based analysis.

In conclusion, MRI is a very attractive candidate for the identification of inexpensive and noninvasive surrogate biomarkers of A*β* deposition because it is widely available, and routinely assessed in clinical practice. Exploring biomarkers from a range of modalities and/or disciplines already well established in AD research and clinical practice may also provide a less invasive, less expensive, and more practical way to identify individuals with A*β* pathology. Several lines of evidence suggest that clinical measures, genetic risk factors, and peripheral blood protein levels can also reflect the likelihood of having elevated A*β* accumulation and can potentially be useful for assessing the risk for future conversion into AD.[@b54]--[@b59] Together with the work of others, our findings could result in development of multidisciplinary and multimodality biomarkers of brain amyloidosis that are reliable, minimally invasive, simple to perform, and widely available. These may include detailed demographic characteristics such as family history, cognitive performance, and high-throughput biomarker technologies such as genomics and proteomics. Our approach is expected to have value for the identification of individuals likely to be A*β*+ in circumstances where cost or logistical problems prevent A*β* detection using CSF analysis or amyloid PET. This can be used in clinical settings and clinical trials, aiding subject recruitment and evaluation of treatment efficacy. Imputation of the A*β*-positivity status could also complement A*β*-PET by identifying individuals who would benefit the most from this assessment.
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**Table S1.**Demographic information of cognitively healthy elderly subjects in full ADNI-GO/2 study versus ASL-MRI substudy.

**Table S2.** Demographic information of early-MCI subjects in full ADNI-GO/2 study versus ASL-MRI substudy.
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